[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Current State of Cell-Based Assays Market

24 Oct 2011 • by Natalie Aster

 In 2010, the majority of compound screening programmes performed by the biopharmaceutical industry rely on cell-based assays for one particular reason: cell-based assays enable functional measures of target activation in a more relevant and informative setting when compared with biochemical assays. Label-free cellular assays are driving this paradigm forward, with their exquisite sensitivity, robustness, ease of use and flexibility. These assays are now performed routinely throughout early drug discovery from target identification and validation to primary screening, lead identification and lead optimisation and into safety and toxicology. Through their sensitivity to endogenous levels of receptor targets in cell types, closely aligned to the disease processes under study, these technologies provide accurate models of complex biological states, in formats compatible with large-scale drug screening.

Cell-based assays have emerged as a more relevant alternative to biochemical assays involving the use of purified proteins. Witnessing the growth in demand for cell-based assays, a number of cell culture and liquid handling instruments available on the market now allow cell-based screening. Currently available cell-based assays are available in 96-well to 3456-well plate formats for high-throughput screening.

Report Details:

Cell-Based Assays: World Market Prospects 2011-2026
Published: January 2011
Pages: 127
Price: US$ 2,350.00

Report Sample Abstract

Although still a small proportion of the total market, in vitro toxicity testing using cells-based assays will continue to be the growth driver in this market. The toxicity testing market is gradually moving from in vivo animal models to in vitro cell-based assays, as they provide an early indication of the toxicity characteristics of the drug candidates.

Invitrogen Corporation Overview

Invitrogen Corporation is a global life sciences company serving the pharmaceutical and biotechnology companies, as well as academic and government research organisations. Invitrogen delivers a range of products and services, including systems, instruments, reagents, software, and custom services. In November 2008, Invitrogen acquired Applied Biosystems to form a new company named Life Technologies Corporation.

Cell-Based Assay Kits

Invitrogen provides a broad portfolio of cell-based assay kits that use different technology formats. The company holds validated cell lines including some target specific lines for GPCR’s, kinases and nuclear receptors, and some pathway specific cell lines for oncology and immunology.

Invitrogen's Cell-Based Assays, 2010

Technology Format Assay
TR-FRET LanthaScreen
Beta-lactamase Reporter Gene Cell Sensor
Beta-lactamase Reporter Gene GeneBLAzer
Beta-arrestin Tango
Ion Channel Calcium Flux

Source:Invitrogen 2010; Visiongane 2010

More information can be found in the report “ Cell-Based Assays: World Market Prospects 2011-2026 ” by Visiongain.

To order the report or ask for sample pages contact [email protected]


MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970
[email protected]

Analytics & News

Weekly Digest